Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma.
Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma.
复制标题
帕唑帕尼或阿西替尼与程序性细胞死亡蛋白-1激活的树突状细胞细胞因子诱导的杀伤细胞免疫疗法的新辅助组合可能有助于肾细胞癌患者的手术
DOI：
10.21037/tau-21-406
复制
发表时间：
2021-05
影响因子：
2
通讯作者：
Dong P
中科院分区：
文献类型：
--
作者：
Zhang Z;Xiong L;Wu Z;Liu H;Ning K;Peng Y;Yu C;Ding Y;Weng D;Xia J;Jiang L;Guo S;Han H;Zhou F;Dong P
根治性/细胞减少性肾切除术或保留肾单位的手术在某些肿瘤局部晚期或高度复杂的肾癌患者中可能被认为是不安全或不可行的。新辅助治疗可缩小肿瘤体积，便于手术治疗。本研究的目的是评价帕佐帕尼或阿西替尼联合PD-1激活的树突状细胞-细胞因子诱导的 杀伤细胞(PD-1/DC-CIK)细胞免疫治疗的疗效和安全性。回顾分析16例肾癌患者接受新辅助化疗帕佐帕尼(P组，n=9)或阿西替尼(A组，n=7)联合PD-1/DC-CIK细胞免疫治疗的资料。9例有可能行根治性/细胞减少性肾切除术(RN/CN)的患者为局部晚期肿瘤，5例有肾部分切除术(PN)绝对指征的患者为高度复杂的肿瘤。疗效结果基于13名参与者的原发肿瘤、淋巴结和癌栓的体积变化，并进行完整的计算机断层扫描(CT)成像。与治疗相关的毒性和手术并发症也被报道。中位治疗时间为2.1个月，肿瘤体积平均缩小42.30%[四分位数范围(IQR)：19.37-66.78%]。P组和A组肿瘤体积缩小的中位数分别为88.77cm3和15.50cm3(P=0.014)。然而，P组的参与者比A组的参与者更有可能经历3级或4级的治疗相关不良事件(AEs)(44.4%比0)。最后，所有参与者都是新辅助治疗后合适的手术候选者(根据外科医生的评估)，10名参与者接受了手术，包括5例PN，4例RN/CN和1例淋巴清扫。一名孤独的参与者有需要透析的Clavien IV级急性肾功能衰竭，另一名患者有II级淋巴渗漏。帕佐帕尼或阿西替尼联合PD-1/DC-CIK细胞免疫治疗耐受性好，可有效缩小局部晚期或高度复杂的肾癌患者的肿瘤体积。
Radical/cytoreductive nephrectomy or nephron-sparing surgery may be thought to be not safe or unfeasible in some renal cell carcinoma (RCC) patients in which tumor is locally advanced or highly complicated. Neoadjuvant therapy may reduce the volume of the tumor, thus facilitates surgery. The aim the study is to evaluate the efficacy and safety of neoadjuvant combination of pazopanib or axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) cell immunotherapy in those patients. Data from 16 RCC patients who received neoadjuvant pazopanib (Group P, n=9) or axitinib (Group A, n=7) plus PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. A total of 9 participants that were potential candidates for radical/cytoreductive nephrectomy (RN/CN) had locally advanced tumor and 5 participants with partial nephrectomy (PN) absolute indications had highly complicated tumors. The efficacy outcomes were based on volume changes of the primary tumor, lymph nodes, and tumor thrombus in 13 participants with complete computed tomography (CT) imaging. The treatment-related toxicities and surgical complications were also reported. With a median of 2.1 months treatment, the overall volume of the tumors decreased by a median of 42.30% [interquartile range (IQR): 19.37–66.78%]. Specifically, the median reduction of tumor volume was 88.77 and 15.50 cm3 in group P and group A, respectively (P=0.014). However, participants in Group P were more likely to experience grade 3 or 4 treatment-related adverse events (AEs) than those in Group A (44.4% vs. 0). Finally, all participants were candidates for appropriate surgery after neoadjuvant therapy (as assessed by the surgeon), and 10 participants accepted surgery, including 5 PN, 4 RN/CN, and 1 lymph node dissection. A solitary participant had Clavien grade IV acute renal failure required dialysis and another had grade II lymphatic leakage. Neoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK cells immunotherapy was well-tolerated and could effectively reduce the volume of tumors in locally advanced or highly complicated RCC patients.
登录
查看更多内容
影响因子：
8.8
作者：
Suttle, A. B.;Ball, H. A.;Molimard, M.;Hutson, T. E.;Carpenter, C.;Rajagopalan, D.;Lin, Y.;Swann, S.;Amado, R.;Pandite, L.
通讯作者：
Pandite, L.
影响因子：
2.6
作者：
Franceschetti, Marta;Pievani, Alice;Introna, Martino
通讯作者：
Introna, Martino
影响因子：
158.5
作者：
Motzer, Robert J.;Hutson, Thomas E.;Choueiri, Toni K.
通讯作者：
Choueiri, Toni K.
影响因子：
3.9
作者：
Xiao J;Cai Z;Li W;Yang Z;Gong J;Huang Y;Deng Y;Wu X;Wang L;Peng J;Ren D;Lan P;Wang J
通讯作者：
Wang J
PD-1阻断激活的多抗原特异性细胞疗法单独或与阿帕替尼联合治疗晚期实体瘤患者的安全性和有效性：两项前瞻性试验的汇总分析
影响因子：
5.8
作者：
Liang, Lijun;Wen, Yixuan;Jiang, Xiaodong
通讯作者：
Jiang, Xiaodong